StockNews.com Downgrades BioLife Solutions (NASDAQ:BLFS) to Sell

BioLife Solutions (NASDAQ:BLFS) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Monday.

Other research analysts also recently issued reports about the stock. Benchmark reiterated a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright increased their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Northland Securities lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. Finally, KeyCorp upped their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.

BioLife Solutions Trading Down 0.0 %

NASDAQ:BLFS opened at $22.83 on Monday. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -21.54 and a beta of 2.04. BioLife Solutions has a one year low of $14.84 and a one year high of $29.55. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The business’s 50-day simple moving average is $26.19 and its 200 day simple moving average is $25.55.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. The company had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period in the prior year, the company posted ($0.21) EPS. As a group, sell-side analysts predict that BioLife Solutions will post -0.3 earnings per share for the current fiscal year.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, insider Sarah Aebersold sold 5,632 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $24.96, for a total value of $140,574.72. Following the sale, the insider now directly owns 45,860 shares in the company, valued at approximately $1,144,665.60. This trade represents a 10.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Troy Wichterman sold 987 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74. Following the transaction, the chief financial officer now owns 121,779 shares of the company’s stock, valued at $3,290,468.58. This represents a 0.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,117 shares of company stock valued at $534,442 in the last quarter. Insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

Large investors have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC acquired a new position in BioLife Solutions during the 4th quarter valued at about $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in BioLife Solutions in the 4th quarter valued at about $31,000. 1620 Investment Advisors Inc. lifted its holdings in BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 675 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of BioLife Solutions by 27.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock worth $117,000 after purchasing an additional 950 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in BioLife Solutions during the fourth quarter valued at approximately $171,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.